Permissibility of Various Colorectal Cancer Cell Lines to Tanapox Virus
MetadataShow full item record
Oncolytic virotherapy represents an innovative and emerging approach to cancer therapy that employs replication-competent virus in the targeted and efficient destruction of cancer cells. Tanapox virus (TPV), a member of the Poxviridae family, is considered as a candidate for oncolytic viral therapy because TPV is capable of replicating in human cell lines, and under normal conditions TPV only produces mild infections, resulting in a relatively safe virus to work with (Seibert et al, 2011). This study aimed to determine the susceptibility and extent of productivity/replication of TPV Kenya (TPV) modified with the insertion of enhanced green fluorescence protein (TPV -GFP), in seven distinct cell lines (OMK, HCT -116, ACHN, COL0-205, WI-38, WiDr, and HeLa). Flourescence and phase imaging as well as cytopathic effect (CPE) were examined in determining the efficiency of TPV -GFP viral replication in vitro. All of the examined cell lines were permissive to TPV-GFP, however cancerous cell lines (HCT-116, ACHN, COL0-205, and WiDr) exhibit preferential infectivity to TPV -GFP as evident by a greater extent of GFP expression and a faster rate of cellular monolayer destruction. Non-cancerous human lung fibroblast WI-38 and HeLa cells were least permissive to TPV -GFP replication. OMK and HCT -116 cells experienced morphological changed upon infection and cell size did not influence infection. Preliminary results indicate that TPVGFP has the potential to be developed for oncolytic therapy.